Non-myeloablative allogeneic stem cell transplant in a patient with refractory systemic lupus erythematosus.

摘要

Systemic lupus erythematosus (SLE) is usually treated with immunosuppressives and steroids. Autologous stem cell transplantation (auto-SCT) following immunoablative chemotherapy is a newer therapy for severe SLE.1'2 Non-myeloablative auto-SCT has been studied in patients with SLE with promising results.2 Studies have reported 5-year disease-free survival of 50 and 55%, respectively.2 The treatment-related mortality ranged from 2 to 13%.2 Myeloablative allogeneic stem cell transplantation (MST) has been studied for SLE patients. However, high treatment-related mortality associated with MST mitigates the potential benefit and thus cannot be a routine choice of treatment for patients with SLE.